Gene · 8467
Papers1,650
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 1,650
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Novel Biotherapeutics Targeting Biomolecular and Cellular Approaches in Diabetic Wound Healing. | Biomedicines | 2023 | 36831151 | PubTator, text mining | PubMed |
| Identification of Chromatin Regulatory Factors Related to Immunity and Treatment of Alzheimer's Disease. | J Mol Neurosci | 2023 | 36826468 | PubTator, text mining | PubMed |
| Till SMARCA5 loss do nucleosomes part. | Mol Cell | 2023 | 36804911 | PubTator, text mining | PubMed |
| Circ_0001052 promotes cardiac hypertrophy via elevating Hipk3. | Aging (Albany NY) | 2023 | 36800233 | PubTator, text mining | PubMed |
| Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer. | Nat Commun | 2023 | 36788224 | PubTator, text mining | PubMed |
| Circular RNAs as a Diagnostic and Therapeutic Target in Cardiovascular Diseases. | Int J Mol Sci | 2023 | 36768449 | PubTator, text mining | PubMed |
| The miR-100-5p Targets SMARCA5 to Regulate the Apoptosis and Intracellular Survival of BCG in Infected THP-1 Cells. | Cells | 2023 | 36766816 | PubTator, text mining | PubMed |
| MicroRNAs in the Pathogenesis, Prognostication and Prediction of Treatment Resistance in Soft Tissue Sarcomas. | Cancers (Basel) | 2023 | 36765536 | PubTator, text mining | PubMed |
| The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma. | Front Genet | 2023 | 36755568 | PubTator, text mining | PubMed |
Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. | Dis Markers | 2023 | 36741910 | PubTator, text mining | PubMed |
| Circular RNA SMARCA5 inhibits cholangiocarcinoma via microRNA-95-3p/tumor necrosis factor receptor associated factor 3 axis. | Anticancer Drugs | 2023 | 36727735 | PubTator, text mining | PubMed |
| Protein degradation: expanding the toolbox to restrain cancer drug resistance. | J Hematol Oncol | 2023 | 36694209 | PubTator, text mining | PubMed |
| Circular RNA SMARCA5 Modulates Epithelial-Mesenchymal Transformation, Proliferation, and Metastasis of Nasopharyngeal Carcinoma Cells via microRNA-582-3p/Phosphatase and Tensin Homolog Axis. | Evid Based Complement Alternat Med | 2023 | 36686977 | PubTator, text mining | PubMed |
| Bromodomain (BrD) Family Members as Regulators of Cancer Stemness-A Comprehensive Review. | Int J Mol Sci | 2023 | 36674511 | PubTator, text mining | PubMed |
| Small molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration. | Cell Biosci | 2023 | 36647159 | PubTator, text mining | PubMed |
| Fibril treatment changes protein interactions of tau and α-synuclein in human neurons. | J Biol Chem | 2023 | 36634849 | PubTator, text mining | PubMed |
| Human SMARCA5 is continuously required to maintain nucleosome spacing. | Mol Cell | 2023 | 36630954 | PubTator, text mining | PubMed |
| Characterizing crosstalk in epigenetic signaling to understand disease physiology. | Biochem J | 2023 | 36630129 | PubTator, text mining | PubMed |
| Ribosome biogenesis in disease: new players and therapeutic targets. | Signal Transduct Target Ther | 2023 | 36617563 | PubTator, text mining | PubMed |
| Research progress on the circRNA‑mediated regulation of tumor angiogenesis through ceRNA mechanisms (Review). | Oncol Rep | 2023 | 36416347 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8467/papers?page=10